MIM
DICE

MetLife Investment Management’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

MetLife Investment Management’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-20,543
Closed -$954K – 3022
2023
Q2 		$954K Buy
20,543
+1,692
+9% +$58.5K 0.01% 1295
2023
Q1 		$540K Hold
18,851
– – ﹤0.01% 1591
2022
Q4 		$588K Buy
18,851
+2,930
+18% +$95.6K ﹤0.01% 1536
2022
Q3 		$323K Hold
15,921
– – ﹤0.01% 1954
2022
Q2 		$247K Buy
15,921
+6,450
+68% +$111K ﹤0.01% 2164
2022
Q1 		$181K Buy
9,471
+3,377
+55% +$60.3K ﹤0.01% 2408
2021
Q4 		$154K Buy
+6,094
New +$179K ﹤0.01% 2211

MetLife Investment Management's DICE Position: Q3 2023 in Review

MetLife Investment Management sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 20,543 shares — an estimated $954K sold.

MetLife Investment Management first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $954K in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

  • MetLife Investment Management reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • MetLife Investment Management sold 20,543 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $954K.
  • MetLife Investment Management first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
  • MetLife Investment Management's DICE Therapeutics, Inc. Common Stock position peaked at $954K in Q2 2023.
  • 0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on MetLife Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.